Modern nucleic acid therapies (mRNA vaccines, gene editing) rely on effective delivery to address in vivo enzymatic degradation and poor cellular uptake. Advanced non-viral lipid carriers shield cargo, enable endosomal escape and overcome barriers like dense tumor microenvironments for maximal cytosolic availability.
Creative Biolabs offers custom lipid-based vector development via proprietary lipid engineering, high-throughput screening and target-responsive design. It provides tailored vectors based on therapeutic application, target tissue and administration route, ensuring cargo protection, uptake enhancement and functional delivery.
Creative Biolabs offers highly specialized development services across the full spectrum of lipid-based carriers, ensuring the optimal system is selected and engineered for your specific therapeutic goal.
Fig.1 LBNPs used for drug delivery and their types.1
| Carrier Type | Core Composition & Structural Features | Key Advantages | Typical Application Scenarios |
|---|---|---|---|
| Lipoplex (LP) | Formed via electrostatic interactions between cationic lipids and anionic nucleic acid backbones; simple binary system. | Easy to produce; low manufacturing complexity. | Basic nucleic acid delivery (e.g., siRNA, plasmid DNA) for in vitro research or simple in vivo models. |
| Lipid Nanoparticle (LNP) | Multi-component system: ionizable lipids, phospholipids, cholesterol, PEG lipids; formulated via microfluidics for uniform size. | Current "gold standard" for nucleic acid delivery; tight size control, high stability, efficient endosomal escape. | mRNA vaccines, gene editing tools (e.g., CRISPR), systemic delivery of therapeutic nucleic acids (liver, muscle targeting). |
| Solid Lipid Nanoparticle (SLN) | Solid, homogenous lipid matrix (e.g., triglycerides, waxes) at body temperature; first-generation lipid carrier. | Excellent physical stability; controlled release kinetics; superior cargo protection. | Oral delivery of nucleic acids, dermal therapeutic formulations, controlled-release drug delivery. |
| Nanostructured Lipid Carrier (NLC) | Second-generation lipid carrier; core of mixed solid + liquid lipids (unstructured matrix). | Higher drug loading capacity than SLNs; prevents cargo expulsion during storage; low systemic toxicity. | Long-acting injectable nucleic acid therapeutics, localized delivery (e.g., tumor, mucosal tissues), high-dose cargo delivery. |
| Cation Nanoemulsion (CNE) | Oil phase dispersed in aqueous phase; stabilized by cationic lipids; small droplet size (~200 nm). | Potent delivery efficiency; induces robust immune response at low doses. | Self-amplifying RNA (saRNA) vaccines, infectious disease vaccines, cancer immunotherapy. |
| Native Lipoprotein (LPT) | Biological carriers (e.g., HDL, LDL); utilize natural lipid transport pathways. | Exploits body's native transport systems; high targeting specificity to LPT receptor-expressing tissues. | Targeted delivery to tissues with high LPT receptors (e.g., liver, atherosclerotic plaques), hydrophobic drug/nucleic acid co-delivery. |
| Synthetic Lipoprotein (sLPT) | Engineered mimics of native LPTs; composed of peptides/phospholipids; controlled size/composition. | Avoids variability/immunogenicity of native LPTs; retains targeting ability; barrier penetration. | Targeted delivery to inflamed tissues, liver-directed gene therapy, delivery across biological barriers (e.g., blood-brain barrier). |
Our comprehensive workflow is designed for transparency and efficiency, providing a clear roadmap from initial concept to a validated, preclinical-ready vector. This structured approach is ideal for visualization and ensures precise collaboration at every stage.
Provide the target RNA sequence (complete sequence and purity data for mRNA, sgRNA, siRNA, etc.), specific cell lines or in vivo models for initial validation (target cell line/tissue model), and information on desired dosage/route of administration, including therapeutic window goals and intended delivery methods.
Use computational modeling to screen proprietary and commercial lipid components (e.g., ionizable lipids, helper lipids), with the core goal of maximizing endosomal escape potential.
The typical timeframe for this service is 8-16 weeks, depending on the complexity of the cargo and the depth of in vivo validation required. Custom synthesis of novel lipid components may extend this period.
Creative Biolabs' Lipid-based Vector Development platform delivers customized, functional, and scalable non-viral delivery systems engineered for success in complex biological environments. We are your partner in unlocking the true potential of nucleic acid therapeutics.
Custom-Engineered LNP Systems
We engineer, not just formulate—each vector is custom-designed for your specific therapeutic cargo (mRNA, saRNA, sgRNA) and target tissue, ensuring maximum in vivo functional efficacy.
Proprietary Ionizable Lipid Library
Access our exclusive next-gen lipid library, optimized for superior endosomal escape, reduced immunogenicity, and low hepatotoxicity, avoiding limitations of standard commercial lipids.
High-Throughput & Scalable Formulation
Use microfluidics-based screening to quickly identify optimal parameters (PDI <0.1, 50-150 nm), delivering protocols ready for cGMP manufacturing scale-up.
Intelligent Targeting for Complex Tissues
Develop surface-modified, TME-responsive (acidic pH, enzyme triggers) carriers for deep penetration and specific uptake in challenging sites (solid tumors, brain, lung).
Complete Process Transfer & Quality Assurance
Provide comprehensive docs, analytical validation (e.g., high-resolution cryo-EM), and tech transfer support, adhering to QbD principles for regulatory success.
A: Absolutely. We screen our proprietary ionizable lipid library and optimize formulation pKa to destabilize endosomal membranes, ensuring payload release into the cytoplasm. Contact us to analyze your current data.
A: We design TME-responsive carriers that use tumors' unique conditions (low pH, high enzyme expression) to degrade ECM barriers or trigger site-specific cargo release, overcoming traditional carriers' poor passive penetration.
A: Yes. Our workflow uses high-throughput microfluidic mixing (cGMP-compatible) to create robust, reproducible protocols that easily translate to large-scale synthesis, avoiding later optimization bottlenecks.
A: Lipoplexes have serum instability and high toxicity; NLCs/CNEs offer better stability, lower toxicity, and higher encapsulation efficiency. NLCs also have higher drug loading via their amorphous core.
A: Certainly. Our modular platform integrates your novel lipid into microfluidic screening, testing combinations with our helper lipids to find optimal ratios for stability, uptake, and efficacy.
Creative Biolabs offers more than a service; we offer a strategic partnership in therapeutic delivery. By integrating cutting-edge lipid chemistry with deep biological insight into barriers like endosomal escape and TME penetration, we empower our clients to unlock the full potential of their nucleic acid and nanomedicine programs. We provide end-to-end support, from rational design and high-throughput screening to final-stage characterization and protocol handover.
Contact Our Team for More Information and to Discuss Your Project| Cat. No | Product Name | Promoter |
|---|---|---|
| CAT#: GTVCR-WQ001MR | IVTScrip™ pT7-mRNA-EGFP Vector | T7 |
| CAT#: GTVCR-WQ002MR | IVTScrip™ pT7-VEE-mRNA-EGFP Vector | T7 |
| CAT#: GTVCR-WQ003MR | IVTScrip™ pT7-VEE-mRNA-FLuc Vector | T7 |
| CAT#: GTVCR-WQ87MR | IVTScrip™ pT7-VEE-mRNA-Anti-SELP, 42-89-glycoprotein Vector | T7 |
| Cat. No | Product Name | Type |
|---|---|---|
| CAT#: GTTS-WQ001MR) | IVTScrip™ mRNA-EGFP (Cap 1, 30 nt-poly(A)) | Reporter Gene |
| CAT#: GTTS-WK18036MR | IVTScrip™ mRNA-Human AIMP2, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) | Enzyme mRNA |
| (CAT#: GTTS-WQ004MR) | IVTScrip™ mRNA-Fluc (Cap 1, 30 nt-poly(A)) | Reporter Gene |
| (CAT#: GTTS-WQ009MR) | IVTScrip™ mRNA-β gal (Cap 1, 30 nt-poly(A)) | Reporter Gene |
Reference
